Dr. RASHMI KUMARI

Dr. BHAWESH SAHA, Dr. VIDYA BHUSHAN KUMAR, Dr. Priyanshi Awasthi

Abstract

To evaluate the effects of topical ROCK inhibitor, Ripatec 0.4%.in refractory glaucoma patients as add on therapy,a prospective interventional study at a tertiary eye centre was conducted between Dec19-March 20 .25 eyes refractory glaucoma with uncontrolled IOP despite maximal glaucoma medication were included in the study .Topical Ripatec 0.4% BD was added to the existing medical regimen. Follow up was done at 1, 2, 3, 4, and 8 weeks when intraocular pressure (IOP) and adverse events were evaluated. Baseline mean IOP was 31.5 +/- 3.4 mm Hg and mean IOP reductions of the last visit was -8.25 +/- 1.2 mm Hg was statistically significant with 0.4% ripasudil. Conjunctival hyperemia was found in 5 patients (20%) , 3 patients (12%) reported blepharitis. Conclusion : Topical Ripasudil in refractory glaucoma ,cause significant reduction in IOP(20%) and is well tolerated. ROCK inhibitors could be given a trial before switching over to incisional surgeries.